Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729417 | 0.80 | BRD4 (0.44) | BRD4BRD9BRD7L3MBTL1 | |
| SCHEMBL22729829 | 0.80 | BRD4 (0.50) | BRD4 | |
| SCHEMBL17963571 | 0.75 | CCNT1 (0.33) | BRD4CCNT1CDK9L3MBTL1GRM2 | |
| SCHEMBL31589831 | 0.73 | PKM (0.43) | BRD4BRD9BRD7 | |
| SCHEMBL17879710 | 0.69 | BRD4 (0.41) | BRD4BRD9BRD7L3MBTL1 | |
| SCHEMBL31590252 | 0.69 | BRD4 (0.43) | BRD4 | |
| SCHEMBL15801423 | 0.69 | MAPT (0.48) | BRD4GRM2 | |
| SCHEMBL31590222 | 0.67 | GFER (0.44) | BRD4BRD9BRD7GRM2 | |
| SCHEMBL22729605 | 0.67 | BRD4 (0.31) | BRD4 | |
| SCHEMBL22729432 | 0.66 | LMNA (0.40) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | BRD4 1170/4885BRD9 2497/4885BRD7 1991/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | BRD4 1201/4885BRD9 2508/4885BRD7 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.